Cytokinetics (CYTK) Getting Somewhat Positive Media Coverage, Study Shows

News articles about Cytokinetics (NASDAQ:CYTK) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytokinetics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.1954798294058 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

CYTK traded up $0.15 during trading on Tuesday, reaching $7.90. 202,248 shares of the stock were exchanged, compared to its average volume of 370,141. The company has a debt-to-equity ratio of 0.29, a quick ratio of 8.46 and a current ratio of 8.46. The company has a market cap of $407.76, a price-to-earnings ratio of -3.04 and a beta of 1.16. Cytokinetics has a 1 year low of $6.75 and a 1 year high of $17.20.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.04). The firm had revenue of ($0.02) million for the quarter, compared to analysts’ expectations of $4.83 million. Cytokinetics had a negative return on equity of 96.95% and a negative net margin of 172.27%. analysts predict that Cytokinetics will post -1.81 EPS for the current fiscal year.

A number of analysts recently weighed in on the company. Cantor Fitzgerald restated a “hold” rating and issued a $10.00 price target on shares of Cytokinetics in a research note on Wednesday, January 17th. HC Wainwright set a $20.00 price target on Cytokinetics and gave the company a “buy” rating in a research note on Friday, January 19th. BidaskClub upgraded Cytokinetics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 6th. Morgan Stanley lifted their price target on Cytokinetics from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 21st. Finally, Cowen restated a “buy” rating and issued a $11.00 price target on shares of Cytokinetics in a research note on Tuesday, February 20th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $15.67.

In other Cytokinetics news, CEO Robert I. Blum sold 4,000 shares of the business’s stock in a transaction on Thursday, April 5th. The stock was sold at an average price of $7.52, for a total transaction of $30,080.00. Following the sale, the chief executive officer now directly owns 182,701 shares in the company, valued at $1,373,911.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.10% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “Cytokinetics (CYTK) Getting Somewhat Positive Media Coverage, Study Shows” was posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://macondaily.com/2018/04/17/cytokinetics-cytk-getting-somewhat-positive-media-coverage-study-shows.html.

About Cytokinetics

Cytokinetics, Inc operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS).

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply